| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8d810c8de815e240646dfcfa88972204 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4709
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A23K20-111
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A23K50-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-26
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A23K20-142
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A23K20-163
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0095 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-26
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4709
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A23K1-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A23K1-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A23K20-195 |
| filingDate |
2009-09-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fdb702935fd12239c681df3d42f10dd2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e0e141532e10bec3ebfeadb6a7122a1f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f988dce214c9415cde1ae099832b4a63 |
| publicationDate |
2011-07-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-2343089-A1 |
| titleOfInvention |
Utilization of xylitol or its derivatives for taste-masking chemotherapy drugs of the quinolone-o-naphthyridone carboxylic acid group administrated in food intended for pigs |
| abstract |
Utilization of xylitol or its derivatives for taste-masking chemotherapy drugs of the quinolone-o-naftiridon carboxylic acid group especially enrofloxacin, administered in food intended for pigs including water. The xylitol may be used alone or together with other synergists, in particular arginine. The xylitol is in a proportion by weight lying between 1 and 100 parts of xylitol to 1 part of quinolone, and more particularly between 20 and 70 parts of xylitol to 1 part of chemotherapy drug. Arginine, when present, is in a proportion by weight lying between 0.5 to 2 parts of arginine to 1 part of chemotherapy drug. The utilization of xylitol furthermore comprises combination with other synergists of xylitol or its derivates, not being arginine, to increase the masking effect of the xylitol. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2774489-A1 |
| priorityDate |
2008-09-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |